Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

17.1%

6 terminated/withdrawn out of 35 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

31%

11 trials in Phase 3/4

Results Transparency

76%

16 of 21 completed trials have results

Key Signals

4 recruiting16 with results

Enrollment Performance

Analytics

Phase 2

15(45.5%)

Phase 3

6(18.2%)

Phase 4

5(15.2%)

Phase 1

4(12.1%)

Early Phase 1

3(9.1%)

33Total

Phase 2(15)

Phase 3(6)

Phase 4(5)

Phase 1(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT04984343Phase 2Terminated

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Role: collaborator

NCT03471650Phase 2Active Not Recruiting

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Role: collaborator

NCT06586047Early Phase 1Recruiting

Breast Cancer PSMA PET

Role: collaborator

NCT04461509Phase 2Completed

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

Role: collaborator

NCT03495427Phase 2Recruiting

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Role: collaborator

NCT06099093Phase 4Recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Role: collaborator

NCT06322576Phase 2Terminated

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Role: collaborator

NCT05919329Phase 4Recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Role: collaborator

NCT03939689Phase 2Completed

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Role: lead

NCT04030338Active Not Recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Role: collaborator

NCT03392181Early Phase 1Active Not Recruiting

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Role: collaborator

NCT03525288Phase 2Active Not Recruiting

PSMA-PET Guided Radiotherapy

Role: collaborator

NCT04614766Phase 1Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Role: collaborator

NCT04727736Phase 2Terminated

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Role: collaborator

NCT04457245Phase 3Terminated

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Role: collaborator

NCT04266392Early Phase 1Completed

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Role: collaborator

NCT01856933Phase 2Completed

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

Role: collaborator

NCT02981368Phase 2Completed

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Role: lead

NCT03739684Phase 3Completed

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Role: lead

NCT00605644Phase 2Completed

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Role: collaborator